209 related articles for article (PubMed ID: 29119938)
1. Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature.
Sousa JB; Fresco P; Diniz C; Goncalves J
Recent Pat Anticancer Drug Discov; 2018; 13(1):40-69. PubMed ID: 29119938
[TBL] [Abstract][Full Text] [Related]
2. P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future.
Borah P; Deka S; Mailavaram RP; Deb PK
Curr Pharm Des; 2019; 25(26):2792-2807. PubMed ID: 31333097
[TBL] [Abstract][Full Text] [Related]
3. Adenosine Receptors as Novel Targets for the Treatment of Various Cancers.
Gorain B; Choudhury H; Yee GS; Bhattamisra SK
Curr Pharm Des; 2019; 25(26):2828-2841. PubMed ID: 31333092
[TBL] [Abstract][Full Text] [Related]
4. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potency of pharmacological adenosine receptor agonist/antagonist in angiogenesis, current status and perspectives.
Bahreyni A; Khazaei M; Rajabian M; Ryzhikov M; Avan A; Hassanian SM
J Pharm Pharmacol; 2018 Feb; 70(2):191-196. PubMed ID: 29057476
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors.
Jamwal S; Mittal A; Kumar P; Alhayani DM; Al-Aboudi A
Curr Pharm Des; 2019; 25(26):2892-2905. PubMed ID: 31333104
[TBL] [Abstract][Full Text] [Related]
7. Adenosine receptor ligands: where are we, and where are we going?
Tuccinardi T; Martinelli A
Curr Top Med Chem; 2010; 10(10):941. PubMed ID: 20681944
[No Abstract] [Full Text] [Related]
8. Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy.
Franco R; Rivas-Santisteban R; Navarro G; Reyes-Resina I
Cells; 2021 Oct; 10(11):. PubMed ID: 34831054
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in adenosine receptor ligands and their potential as novel drugs.
Müller CE; Jacobson KA
Biochim Biophys Acta; 2011 May; 1808(5):1290-308. PubMed ID: 21185259
[TBL] [Abstract][Full Text] [Related]
10. Contractile effects and receptor analysis of adenosine-receptors in human detrusor muscle from stable and neuropathic bladders.
Pakzad M; Ikeda Y; McCarthy C; Kitney DG; Jabr RI; Fry CH
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):921-9. PubMed ID: 27185496
[TBL] [Abstract][Full Text] [Related]
11. Modifications on the Amino-3,5-dicyanopyridine Core To Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic Activity.
Betti M; Catarzi D; Varano F; Falsini M; Varani K; Vincenzi F; Pasquini S; di Cesare Mannelli L; Ghelardini C; Lucarini E; Dal Ben D; Spinaci A; Bartolucci G; Menicatti M; Colotta V
J Med Chem; 2019 Aug; 62(15):6894-6912. PubMed ID: 31306001
[TBL] [Abstract][Full Text] [Related]
12. Medicinal chemistry of adenosine, P2Y and P2X receptors.
Jacobson KA; Müller CE
Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of Adenosine Receptors: The State of the Art.
Borea PA; Gessi S; Merighi S; Vincenzi F; Varani K
Physiol Rev; 2018 Jul; 98(3):1591-1625. PubMed ID: 29848236
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
Jensen K; Johnson LA; Jacobson PA; Kachler S; Kirstein MN; Lamba J; Klotz KN
Naunyn Schmiedebergs Arch Pharmacol; 2012 May; 385(5):519-25. PubMed ID: 22249336
[TBL] [Abstract][Full Text] [Related]
15. Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives.
Deb PK; Deka S; Borah P; Abed SN; Klotz KN
Curr Pharm Des; 2019; 25(25):2697-2715. PubMed ID: 31333094
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature.
Kaur R; Kaur P; Sharma S; Singh G; Mehndiratta S; Bedi PM; Nepali K
Recent Pat Anticancer Drug Discov; 2015; 10(1):23-71. PubMed ID: 25230072
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode.
Lagarias P; Vrontaki E; Lambrinidis G; Stamatis D; Convertino M; Ortore G; Mavromoustakos T; Klotz KN; Kolocouris A
J Chem Inf Model; 2018 Apr; 58(4):794-815. PubMed ID: 29485875
[TBL] [Abstract][Full Text] [Related]
18. Theoretical structure-activity studies of adenosine A1 ligands: requirements for receptor affinity.
Dooley MJ; Kono M; Suzuki F
Bioorg Med Chem; 1996 Jun; 4(6):923-34. PubMed ID: 8818243
[TBL] [Abstract][Full Text] [Related]
19. Ribose modified nucleosides and nucleotides as ligands for purine receptors.
Jacobson KA; Ravi RG; Nandanan E; Kim HS; Moro S; Kim YC; Lee K; Barak D; Marquez VE; Ji XD
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):333-41. PubMed ID: 11563046
[TBL] [Abstract][Full Text] [Related]
20. A1 adenosine receptors and their ligands: overview and recent developments.
Müller CE
Farmaco; 2001; 56(1-2):77-80. PubMed ID: 11347971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
